Stifel lowered the firm’s price target on Fate Therapeutics (FATE) to $3 from $5 and keeps a Hold rating on the shares. Key updates the firm will be tracking throughout 2025 include FT819 data and FT825 in solid tumors, notes the analyst, whose updated model now only includes FT819 in moderate-to-severe systemic lupus erythematosus.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FATE:
- Fate Therapeutics price target lowered to $4 from $5 at Wells Fargo
- Cautious Outlook on Fate Therapeutics Amid FT819 Program Developments and Financial Uncertainties
- Fate Therapeutics Advances CAR T-cell Programs Amid Financial Losses
- Fate Therapeutics reports Q4 EPS (44c), consensus (42c)
- FATE Earnings this Week: How Will it Perform?